Maternal serum tumour necrosis factor receptor 1 (TNF-R1) at 30–33 weeks in the prediction of preeclampsia

References

• World Health Organization. Make every mother and child count. World Health Report, 2005. Geneva, Switzerland: World Health Organization; 2005
   Google Scholar
• Confidential Enquiry into Maternal and Child Health (CEMACH). Perinatal mortality 2006: England, Wales and Northern Ireland. London: CEMACH; 2008
   Google Scholar
• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–7
   PubMed Web of Science ®Google Scholar
• Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4:700–8
   PubMed Web of Science ®Google Scholar
• Granger JP, Alexander BT, Llinas MT, et al. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001;38:718–22
   PubMed Web of Science ®Google Scholar
• Dekker GA, Sibai B. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998;179:1359–75
   PubMed Web of Science ®Google Scholar
• Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240–9
   PubMed Web of Science ®Google Scholar
• Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1–20
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717–25
   PubMed Web of Science ®Google Scholar
• Vince GS, Starkey PM, Austgulen R, et al. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with preeclampsia. Br J Obstet Gynaecol 1995;102:20–5
   PubMedGoogle Scholar
• Williams MA, Mahomed K, Farrand A, et al. Plasma tumor necrosis factor-alpha soluble receptor p 55 (sTNFp55) concentrations in eclamptic, preeclamptic and normotensive pregnant Zimbabwean women. J Reprod Immunol 1998;40:159–73
   PubMed Web of Science ®Google Scholar
• Sanchez SE, Zhang C, Williams MA, et al. Tumor necrosis factor-alpha soluble receptor p55 (sTNFp55) and risk of preeclampsia in Peruvian women. J Reprod Immunol 2000;47:49–63
   PubMed Web of Science ®Google Scholar
• Visser W, Beckmann I, Knook MA, Wallenburg HC. Soluble tumor necrosis factor receptor II and soluble cell adhesion molecule 1 as markers of tumor necrosis factor-alpha release in preeclampsia. Acta Obstet Gynecol Scand 2002;81:713–19
   PubMed Web of Science ®Google Scholar
• Hamai Y, Fujii T, Yamashita T, et al. Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia. Am J Reprod Immunol 1997;38:89–93
   PubMed Web of Science ®Google Scholar
• Leal AM, Poon LC, Frisova V, et al. First-trimester maternal serum tumor necrosis factor receptor-1 and pre-eclampsia. Ultrasound Obstet Gynecol 2009;33:135–41
   PubMed Web of Science ®Google Scholar
• Robinson HP, Fleming JE. A critical evaluation of sonar “crown rump length” measurements. Br J Obstet Gynaecol 1975;82:702–10
   PubMedGoogle Scholar
• Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7–15
   PubMed Web of Science ®Google Scholar
• Lai J, Syngelaki A, Poon LCY, et al. Maternal serum soluble endoglin (sEng) at 30–33 weeks in the prediction of preeclampsia. Fetal Diagn Ther 2013. DOI: 10.1159/000343220
   Google Scholar
• Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988;158:892–8
   PubMed Web of Science ®Google Scholar
• Lai J, Poon LCY, Pinas A, et al. Uterine artery Doppler at 30–33 weeks’ gestation in the prediction of preeclampsia. Fetal Diagn Ther 2013. DOI: 10.1159/000343665
   Google Scholar
• Kronborg CS, Gjedsted J, Vittinghus E, et al. Longitudinal measurement of cytokines in pre-eclamptic and normotensive pregnancies. Acta Obstet Gynecol Scand 2001;90:791–6
   Google Scholar
• Szarka A, Rigo J, Lázár L, et al. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010;11:59
   PubMed Web of Science ®Google Scholar
• Brewster JA, Orsi NM, Gopichandran N, et al. Gestational effects on host inflammatory response in normal and pre-eclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 2008;140:21–6
   PubMed Web of Science ®Google Scholar
• Kucukgoz GU, Tuncay OF, Baris GA, et al. An analysis of C-reactive protein, procalcitonin, and D-Dimer in pre-eclamptic patients. Am J Reprod Immunol 2012;68:331–7
   PubMedGoogle Scholar
• Savvidou MD, Lees CC, Para M, et al. Levels of C-reactive protein in pregnant women who subsequently develop pre-eclampsia. BJOG 2002;109:297–301
   PubMed Web of Science ®Google Scholar
• Gandevani SB, Banaem LM, Mohamadi B, et al. Association of high-sensitivity C-reactive protein serum levels in early pregnancy with the severity of preeclampsia and fetal birth weight. J Perinat Med 2012;40:601–5
   PubMed Web of Science ®Google Scholar
• Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011;29:183–96
   PubMed Web of Science ®Google Scholar
• Roberge S, Villa P, Nicolaides KH, et al. Early administration of low dose aspirin for the prevention of preterm and term pre-eclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141–6
   PubMed Web of Science ®Google Scholar
• Koopmans CM, Bijlenga D, Groen H, et al; HYPITAT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009;374:979–88
   PubMed Web of Science ®Google Scholar
• Poon LC, Kametas NA, Maiz N, et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009;53:812–18
   PubMed Web of Science ®Google Scholar